WO2006019685A3 - Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides - Google Patents

Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides Download PDF

Info

Publication number
WO2006019685A3
WO2006019685A3 PCT/US2005/024533 US2005024533W WO2006019685A3 WO 2006019685 A3 WO2006019685 A3 WO 2006019685A3 US 2005024533 W US2005024533 W US 2005024533W WO 2006019685 A3 WO2006019685 A3 WO 2006019685A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
alzheimer
disease
amyloid peptide
preparation
Prior art date
Application number
PCT/US2005/024533
Other languages
English (en)
Other versions
WO2006019685A2 (fr
Inventor
Donald W Landry
Shixian Deng
Tae-Wan Kim
Jeong Hill Park
Original Assignee
Univ Columbia
Donald W Landry
Shixian Deng
Tae-Wan Kim
Jeong Hill Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/961,346 external-priority patent/US20060014704A1/en
Application filed by Univ Columbia, Donald W Landry, Shixian Deng, Tae-Wan Kim, Jeong Hill Park filed Critical Univ Columbia
Priority to CA002573699A priority Critical patent/CA2573699A1/fr
Priority to JP2007521534A priority patent/JP2008506686A/ja
Priority to EP05788885A priority patent/EP1778715A2/fr
Priority to MX2007000562A priority patent/MX2007000562A/es
Publication of WO2006019685A2 publication Critical patent/WO2006019685A2/fr
Publication of WO2006019685A3 publication Critical patent/WO2006019685A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)

Abstract

La présente invention concerne de nouveaux composés de ginsenoside, des compositions (par ex., des compositions pharmaceutiques) renfermant ces composés de ginsenoside ainsi que des procédés de synthèse de ces composés de ginsenoside. En outre, la présente invention concerne des méthodes destinées à inhiber la production de peptides bêta-amyloïdes et des méthodes destinées à traiter ou prévenir un état pathologique, et notamment les maladies neurodégénératives (par ex., la maladie d'Alzheimer), au moyen de ces composés de ginsenoside.
PCT/US2005/024533 2004-07-16 2005-07-11 Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides WO2006019685A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002573699A CA2573699A1 (fr) 2004-07-16 2005-07-11 Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides
JP2007521534A JP2008506686A (ja) 2004-07-16 2005-07-11 ベータ−アミロイドペプチドの形成を阻害することによるアルツハイマー病治療用化合物及び製造
EP05788885A EP1778715A2 (fr) 2004-07-16 2005-07-11 Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides
MX2007000562A MX2007000562A (es) 2004-07-16 2005-07-11 Compuestos y su preparacion para el tratamiento de la enfermedad de alzheimer al inhibir la produccion de peptidos beta-amiloideos.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58843304P 2004-07-16 2004-07-16
US60/588,433 2004-07-16
US10/961,346 US20060014704A1 (en) 2004-07-16 2004-10-07 Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production
US10/961,346 2004-10-07
US10/963,214 2004-10-12
US10/963,214 US20060014729A1 (en) 2004-07-16 2004-10-12 Compounds and their preparation for the treatment of Alzheimer's disease by inhibiting beta-amyloid peptide production

Publications (2)

Publication Number Publication Date
WO2006019685A2 WO2006019685A2 (fr) 2006-02-23
WO2006019685A3 true WO2006019685A3 (fr) 2006-06-15

Family

ID=35907856

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/024533 WO2006019685A2 (fr) 2004-07-16 2005-07-11 Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides

Country Status (6)

Country Link
EP (1) EP1778715A2 (fr)
JP (1) JP2008506686A (fr)
KR (1) KR20070057779A (fr)
CA (1) CA2573699A1 (fr)
MX (1) MX2007000562A (fr)
WO (1) WO2006019685A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101397327B (zh) * 2007-09-29 2012-01-11 广州天安医药科技有限公司 二氢人参皂苷Rg2的应用
CN104644658A (zh) * 2013-11-22 2015-05-27 富力 人参皂苷Rg3在制备用于预防或/和治疗痴呆病症药物中的应用及药物
CN105753923B (zh) * 2014-12-17 2017-09-29 富力 20(R)‑人参皂苷Rg3多酰基化衍生物、制备及其应用
KR101777920B1 (ko) * 2015-07-27 2017-09-14 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 f1을 포함하는 아밀로이드 플라크 제거용 조성물
CN106046098B (zh) * 2016-06-15 2017-07-11 大连大学 一种乙酰基人参皂苷Rd及其制备方法
KR102375097B1 (ko) 2021-04-01 2022-03-17 주식회사 클로소사이언스 항노화 유전자 klotho의 발현을 유도하는 화합물을 포함하는 퇴행성 신경질환의 예방 또는 치료용 조성물
CN113633650A (zh) * 2021-08-26 2021-11-12 哈尔滨工业大学（威海） 一种抑制淀粉样蛋白产生的稀有人参皂苷及其应用
CN115025106A (zh) * 2022-07-12 2022-09-09 昆明理工大学 人参皂苷Rk3在制备具有神经保护作用药物中的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007732A2 (fr) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Composes efficaces sur le plan pharmaceutique et utilisation associee

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3535588B2 (ja) * 1994-11-18 2004-06-07 株式会社ネオス ジンセノサイドＲｈ２の製造方法
AU9029298A (en) * 1997-08-28 1999-03-16 Cv Technologies Inc. Chemical and pharmacological standardization of herbal extracts
KR100448667B1 (ko) * 2001-04-25 2004-09-13 (주) 디지탈바이오텍 진세노사이드 가수분해물을 함유하는 퇴행성 뇌질환의예방 및 치료용 조성물
WO2004002494A1 (fr) * 2002-05-16 2004-01-08 Digital Biotech Co., Ltd. Composition pour la prevention ou le traitement d'affections cerebrales degeneratives, comprenant un hydrolysat de ginsenosides
KR20040036451A (ko) * 2002-10-26 2004-04-30 한국과학기술연구원 진세노사이드 Ｒｇ３ 또는 진세노사이드 Ｒｈ２를포함하는 글루타메이트 매개 신경독성 억제 조성물
KR20030088417A (ko) * 2003-11-06 2003-11-19 주식회사 케이티앤지 인삼 모상근을 이용한 기억력 증강 신규조성물진세노-제이케이와 그 제조방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002007732A2 (fr) * 2000-07-26 2002-01-31 Cambridge University Technical Services Limited Composes efficaces sur le plan pharmaceutique et utilisation associee

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIN S-H ET AL: "Korean red ginseng saponins with low ratios of protopanaxadiol and protopanaxatriol saponin improve scopolamine-induced learning disability and spatial working memory in mice.", JOURNAL OF ETHNOPHARMACOLOGY., vol. 66, August 1999 (1999-08-01), pages 123 - 129, XP002998588 *
POPOVICH D.G. ET AL: "Structure-function relationship exists for ginsenosides in reducing cell proliferation and inducing apoptosis in the human leukemia (THP-1) cell line.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS., vol. 406, October 2002 (2002-10-01), pages 1 - 8, XP002998587 *

Also Published As

Publication number Publication date
JP2008506686A (ja) 2008-03-06
MX2007000562A (es) 2007-03-30
CA2573699A1 (fr) 2006-02-23
EP1778715A2 (fr) 2007-05-02
KR20070057779A (ko) 2007-06-07
WO2006019685A2 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2006037024A3 (fr) Sels de decitabine
WO2006019685A3 (fr) Composes et leur preparation pour le traitement de la maladie d'alzheimer par inhibition de la production de peptides beta-amyloides
WO2002064083A3 (fr) Synthese de 3-amino-thalidomide et de ses enantiomeres
WO2007064932A3 (fr) Dérivés de pyrrolotriazine utiles pour traiter le cancer par inhibition de la kinase aurora
WO2006034154A3 (fr) Sels de 5-azacytidine
WO2006124012A3 (fr) Composes pour le traitement de la maladie d'alzheimer et pour l'inhibition de la production du peptide amyloide beta
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1940373B8 (fr) 1-fluoro-1-deoxy-scyllo-inositol destine au traitement de la maladie d'alzheimer
EP2305640A3 (fr) Diphenyl-éthers, -amines, -sulfides et -méthanes pour le traitement de maladies respiratoires
TW200628473A (en) Novel heterocycles
HK1104280A1 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
CA2534532A1 (fr) Composes pour le traitement de maladies neurodegeneratives
WO2006138043A3 (fr) Methode et compositions permettant de traiter le diabete et ses complications
WO2004055201A3 (fr) Cholesterol 24-hydroxylase (cyp46) utilisee en tant que cible therapeutique pour le traitement de la maladie d'alzheimer
WO2005092062A3 (fr) Composes destines aux troubles neurodegeneratifs
WO2004073615A8 (fr) Composes de deazaflavine et leurs methodes d'utilisation
WO2005023833A3 (fr) Traitement de maladies neurodegeneratives
EP1958939A3 (fr) Composes pyrazole-amines utilises dans le traitement des troubles neurodegeneratifs
WO2005097114A3 (fr) Composes de thiazole sulfamide utiles pour le traitement des maladies neurodegeneratives
WO2004087880A3 (fr) Composes et leur utilisation dans le traitement du diabete et troubles connexes
WO2007044574A3 (fr) Compositions pharmaceutiques, leurs procedes de preparation, et procedes de traitement
WO2006110447A3 (fr) Derives de pyrimidine
WO2004080374A3 (fr) Diagnostics et therapies pour maladies associees a la phosphodi-esterase 1c (pde1c)
WO2007063428A3 (fr) Méthodes et compositions pharmaceutiques comprenant des acides carboxyalkylsulfoniques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005788885

Country of ref document: EP

Ref document number: 2573699

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/000562

Country of ref document: MX

Ref document number: 2007521534

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1020077002317

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200580031305.8

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2005788885

Country of ref document: EP